Diagnosis and management of atrial fibrillation: an overview.

abstract：Introduction:Cardiovascular diseases are the number one cause of death globally contributing to 37% of all global deaths. A common complication of cardiovascular disease is heart failure, where, in such cases, the only solution would be to conduct a heart transplant. Every 10 minutes a new patient is added to the trans...

journal_title：Cardiovascular therapeutics

authors： Sunjaya AF,Sunjaya AP

更新日期：2019-04-01 00:00:00

abstract：AIMS:cardiopulmonary bypass and cardiac surgery are associated with a significant systemic inflammatory response that has been suggested playing a causative role in the development of perioperative atrial fibrillation (POAF). The goal of this meta-analysis was to determine the efficacy of glucocorticoid prophylaxis in ...

journal_title：Cardiovascular therapeutics

authors： Liu C,Wang J,Yiu D,Liu K

更新日期：2014-06-01 00:00:00

abstract：AIMS:Insulin promotes Akt-dependent prosurvival signaling and reduces experimental ischemia reperfusion injury, but its clinical impact has been limited. Further understanding of the interplay between insulin and Akt in the myocardium of relevant large animal models is needed. We aimed to investigate (1) Akt phosphoryl...

journal_title：Cardiovascular therapeutics

authors： Slettom G,Jonassen AK,Breivik L,Seifert R,Nordrehaug JE

更新日期：2013-12-01 00:00:00

abstract：AIM:To discuss the pathophysiology of iron metabolism in chronic heart failure (CHF) and the current knowledge of the efficacy of intravenous (IV) iron therapy in patients with CHF and identify points of controversy as well as highlight areas for future research. DISCUSSION:Iron deficiency is a recognized complication...

journal_title：Cardiovascular therapeutics

authors： Kang CK,Pope M,Lang CC,Kalra PR

更新日期：2017-12-01 00:00:00

abstract：:The mitochondrial F1F0 ATP synthase is responsible for the majority of ATP production in mammals and does this through a rotary catalytic mechanism. Studies show that the F1F0 ATP synthase can switch to an ATP hydrolase, and this occurs under conditions seen during myocardial ischemia. This ATP hydrolysis causes wasti...

journal_title：Cardiovascular therapeutics

authors： Grover GJ,Malm J

更新日期：2008-01-01 00:00:00

abstract：BACKGROUND:Previous studies have demonstrated that intensive lipid lowering using rosuvastatin results in regression of coronary plaques. However, few data exist regarding lipid profiles over time, drug tolerability, and the effects of prior use of lipid lowering agents in patients on rosuvastatin treatment. Therefore,...

journal_title：Cardiovascular therapeutics

authors： Kawashiri MA,Yamagishi M,Sakamoto T,Takayama T,Hiro T,Daida H,Hirayama A,Saito S,Yamaguchi T,Matsuzaki M,COSMOS Investigators.

更新日期：2013-12-01 00:00:00

abstract：:Sex-specific differences have been definitively demonstrated in cardiovascular (CV) diseases. These differences can also impact on the effects of CV therapies. Female sex is recognized as an independent predictor of thromboembolic risk, particularly in older patients. Most of strokes are due to atrial fibrillation (AF...

journal_title：Cardiovascular therapeutics

authors： Gallù M,Marrone G,Legramante JM,De Lorenzo A,Di Daniele N,Noce A

更新日期：2020-06-18 00:00:00

abstract：AIMS:Data on the clinical impact of gender in "real-life" patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI), receiving clopidogrel, prasugrel, or ticagrelor are limited. We aimed to investigate sex-based differences in clinical outcome of those patients. METHODS:In a prosp...

journal_title：Cardiovascular therapeutics

authors： Xanthopoulou I,Davlouros P,Deftereos S,Hamilos M,Sitafidis G,Kanakakis I,Vavouranakis M,Goudevenos J,Lekakis J,Alexopoulos D

更新日期：2017-08-01 00:00:00

abstract：:The pericardium is composed of visceral and parietal components. In view of the pericardium's simple structure, pathologic processes involving it are understandably few. However, despite a limited number of clinical syndromes, the pericardium is affected by virtually every category of disease, including infectious, ne...

journal_title：Cardiovascular therapeutics

authors： Azam S,Hoit BD

更新日期：2011-10-01 00:00:00

abstract：INTRODUCTION:Platelet activation participates in the development of both coronary artery disease (CAD) and circulating microparticles (MPs). As a commonly used medicine for coronary heart disease, whether aspirin affects the function of MPs remains unclear. AIMS:This study was designed to test MPs from healthy subject...

journal_title：Cardiovascular therapeutics

authors： Cheng G,Shan XF,Wang XL,Dong WW,Li Z,Liu XH,Zhang W,Xing K,Chang FJ

更新日期：2017-08-01 00:00:00

abstract：INTRODUCTION:Statins are known to prevent heart failure (HF). However, it is unclear whether statins as class or type (lipophilic or hydrophilic) improve outcomes of established HF. AIMS:The current meta-analysis was performed to compare the treatment effects of lipophilic and hydrophilic statins on inflammation and c...

journal_title：Cardiovascular therapeutics

authors： Bonsu KO,Reidpath DD,Kadirvelu A

更新日期：2015-12-01 00:00:00

abstract：OBJECTIVE:The transplant vasculopathy as a sign of chronic graft rejection affects both the epicardial and the intramyocardial arteries of the graft. This is at least partially mediated by NO synthases. The aim of this study was to assess possible protective effects of cyclosporine A (CsA), tacrolimus (FK506), and myco...

journal_title：Cardiovascular therapeutics

authors： Bogossian H,Frommeyer G,Ninios I,Bandorski D,Seyfarth M,Matzaroglou C,Lemke B,Eckardt L,Zarse M,Kafchitsas K

更新日期：2016-08-01 00:00:00

abstract：:In patients with ischemic heart disease, the goal of cell therapy is to improve perfusion and function of the damaged heart muscle. For this review, we selected articles that reported the findings from the major clinical studies of cardiovascular stem cell therapy in patients with chronic ischemic heart disease. Becau...

journal_title：Cardiovascular therapeutics

authors： Perin EC,Silva GV

更新日期：2011-06-01 00:00:00

abstract：BACKGROUND:Left ventricular outflow tract obstruction (LVOTO) may complicate an episode of Takotsubo cardiomyopathy (TTC), potentially leading to cardiogenic shock. Beta-blockers are considered the most suitable treatment for such complication. AIM OF THE STUDY:The objective of this study was to evaluate the hemodynam...

journal_title：Cardiovascular therapeutics

authors： Santoro F,Ieva R,Ferraretti A,Fanelli M,Musaico F,Tarantino N,Martino LD,Gennaro LD,Caldarola P,Biase MD,Brunetti ND

更新日期：2016-06-01 00:00:00

abstract：Objective:The drug efficacy may differ among different statins, and evidence from head-to-head comparisons is sparse and inconsistent. The study is aimed at comparing the lipid-lowering/increasing effects of 7 different statins in patients with dyslipidemia, cardiovascular diseases, or diabetes mellitus by conducting s...

journal_title：Cardiovascular therapeutics

authors： Zhang X,Xing L,Jia X,Pang X,Xiang Q,Zhao X,Ma L,Liu Z,Hu K,Wang Z,Cui Y

更新日期：2020-04-23 00:00:00

abstract：:Atrial fibrillation (AF) is the most common sustained cardiac rhythm disturbance found in clinical practice, increasing in prevalence with age. AF is often associated with structural heart disease, although a significant proportion has no detectable heart disease. In the last 2 decades, there has been an increase of 6...

journal_title：Cardiovascular therapeutics

authors： Escobar C,Barrios V,Jimenez D

更新日期：2010-10-01 00:00:00

abstract：INTRODUCTION:Real-world, country-specific studies of dual antiplatelet therapy (DAPT) duration among survivors of acute coronary syndrome (ACS) are important for improving long-term prognosis. AIMS:To investigate DAPT duration after hospital discharge for ACS in Spain. RESULTS:Data from patients enrolled in the Spani...

journal_title：Cardiovascular therapeutics

authors： Bardají A,Leal M,Arrarte V,Garcia-Moll X,Pérez de Isla L,Bueno H

更新日期：2017-04-01 00:00:00

abstract：AIMS:This study aimed to assess prescribers' monitoring for arrhythmic risk with QT-prolonging medications (LQT drugs). METHODS:Over a 6-month period, all inpatients under the care of Cardiologists (Cohort A) and General Physicians (Cohort B) at Aberdeen Royal Infirmary who were prescribed drugs with known risk of Tor...

journal_title：Cardiovascular therapeutics

authors： Choo WK,Turpie D,Milne K,Davidson L,Elofuke P,Whitfield J,Broadhurst P

更新日期：2014-10-01 00:00:00

abstract：Background:Thrombocytopenia was intuitively considered to be associated with higher risk of bleeding and multiple comorbidities after percutaneous coronary intervention (PCI). However, controversial results exist, and the real-world clinical impact of thrombocytopenia in patients undergoing PCI is largely unknown. The ...

journal_title：Cardiovascular therapeutics

authors： Chen Z,Liu Z,Li N,Liu R,Wang M,Wang D,Li C,Li K,Luo F,He Y

更新日期：2021-01-13 00:00:00

abstract：:Acute coronary syndrome (ACS) is a medical emergency often associated with an occlusive coronary event with consequent myocardial underperfusion. Patients require immediate antiplatelet therapy and long-term antithrombotic prophylaxis to reduce the risk of recurrence. Acetylsalicylic acid (ASA) alone or in combination...

journal_title：Cardiovascular therapeutics

authors： Cohen M,Iyer D

更新日期：2014-10-01 00:00:00

abstract：:There is increasing evidence to suggest that chronic heart failure (CHF) is an insulin resistant (IR) state and that the degree of IR correlates with the severity and mortality of CHF. The pathophysiology of IR in CHF has yet to be fully defined. Additionally, it remains to be determined if IR is merely a marker refle...

journal_title：Cardiovascular therapeutics

authors： Wong AK,AlZadjali MA,Choy AM,Lang CC

更新日期：2008-10-01 00:00:00

abstract：BACKGROUND:Doxorubicin (DOX) is an anthracycline antitumor drug. However, its clinical use is limited by dose-dependent cardiotoxicity and even progresses to chronic heart failure (CHF). OBJECTIVE:This study aims to investigate whether the Nrf2 activator, sulforaphane (SFN), can prevent DOX-induced CHF. METHODS:Male ...

journal_title：Cardiovascular therapeutics

authors： Bai Y,Chen Q,Sun YP,Wang X,Lv L,Zhang LP,Liu JS,Zhao S,Wang XL

更新日期：2017-10-01 00:00:00

abstract：:Alternative medications as a term call up many different meanings, significance, and perceptions to various medical practitioners. Some are good; others are bad. A wide range of alternative medications with relevance or connection to cardiovascular (CV) disease have been considered. While many are worthless, others ha...

journal_title：Cardiovascular therapeutics

authors： Whayne TF Jr

更新日期：2010-04-01 00:00:00

abstract：:Transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) are standard procedures for dealing with severe aortic stenosis patients. Researchers have not carried out a systematic review of the volume-outcome relationship in TAVR and SAVR. Our study is intended to address this problem. W...

journal_title：Cardiovascular therapeutics

authors： He J,Zhang Z,Wang H,Cai L

更新日期：2020-04-18 00:00:00

abstract：INTRODUCTION:Nonadherence to secondary preventative medications after stroke is common and is associated with poor outcomes. Numerous strategies exist to promote adherence. We performed a systematic review and meta-analysis to describe the efficacy of strategies to improve adherence to stroke secondary prevention. MET...

journal_title：Cardiovascular therapeutics

authors： Al AlShaikh S,Quinn T,Dunn W,Walters M,Dawson J

更新日期：2016-04-01 00:00:00

abstract：:Recent studies have shown that stromal cell derived factor-1 (SDF-1), first known as a cytokine involved in recruiting stem cells into injured organs, confers myocardial protection in myocardial infarction, which is not dependent on stem cell recruitment but related with modulation of ischemia-reperfusion (I/R) injury...

journal_title：Cardiovascular therapeutics

authors： Jang YH,Kim JH,Ban C,Ahn K,Cheong JH,Kim HH,Kim JS,Park YH,Kim J,Chun KJ,Lee GH,Kim M,Kim C,Xu Z

更新日期：2012-10-01 00:00:00

abstract：INTRODUCTION:Vitamin K antagonists, such as warfarin, are known to promote arterial calcification through blockade of gamma-carboxylation of Matrix-Gla-Protein. It is currently unknown whether other oral anticoagulants such as direct inhibitors of Factor Xa can have protective effects on the progression of aortic valve...

journal_title：Cardiovascular therapeutics

authors： Rattazzi M,Faggin E,Bertacco E,Nardin C,Pagliani L,Plebani M,Cinetto F,Guidolin D,Puato M,Pauletto P

更新日期：2018-08-01 00:00:00

abstract：:Left ventricular hypertrophy (LVH) is a common and independent risk factor for cardiovascular events in patients with coronary artery disease (CAD). Controlling blood pressure is the standard approach to the management of LVH, but this is only partially effective as LVH also persists in normotensive patients. Apart fr...

journal_title：Cardiovascular therapeutics

authors： Mohan M,McSwiggan S,Baig F,Rutherford L,Lang CC

更新日期：2015-02-01 00:00:00

abstract：AIM:Previous studies and national assessments indicate an undertreatment of mineralocorticoid receptor antagonists (MRA) in heart failure with reduced ejection fraction (HFrEF). This study aimed to investigate why MRA is not used to full extent. METHODS:A complete community-based heart failure population was studied. ...

journal_title：Cardiovascular therapeutics

authors： Jonsson A,Norberg H,Bergdahl E,Lindmark K

更新日期：2018-10-01 00:00:00

abstract：AIMS:We performed a multicenter, randomized controlled trial to determine the noninferiority of a novel biodegradable polymer drug-eluting stent (BP-DES), the EXCEL 2 stent, to the first-generation BP-DES, the EXCEL stent. METHODS AND RESULTS:Patients (n = 419) scheduled to undergo percutaneous coronary intervention (...

journal_title：Cardiovascular therapeutics

authors： Xu K,Han Y,Xu B,Yang Y,Wang G,Li H,Sun Y,Tao L,Wang H,Yuan Z,Liu H,Liu J,Jia Y,Ma G,Fu G,Li X,Li S,Wang S,Pu K,CREDIT 2 Investigators.

更新日期：2018-06-01 00:00:00